Status:
RECRUITING
Transforming Ovarian Cancer Diagnostic Pathways
Lead Sponsor:
Professor Sudha Sundar
Collaborating Sponsors:
University of Birmingham
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
Brief Summary
The goal of this observational cohort study is to compare the diagnostic accuracy and cost effectiveness of Risk of Malignancy Algorithm (ROMA) compared with CA125 in the diagnosis of ovarian cancer i...
Detailed Description
A woman's chances of surviving 5 years after Ovarian Cancer (OC) diagnosis drops from 90% if diagnosed at Stage 1 to 15% at Stage 4. Currently, GPs use a blood test called CA125 and ultrasound scan to...
Eligibility Criteria
Inclusion
- Women presenting to primary care with suspected ovarian cancer who are tested for the biomarker CA125 according to current standards of care for investigation of CA125 in the primary care setting.
Exclusion
- Patients presenting to primary care who do not have potential symptoms of ovarian cancer.
- Women with symptoms sometimes associated with ovarian cancer not tested for ovarian cancer.
Key Trial Info
Start Date :
January 23 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 31 2025
Estimated Enrollment :
34000 Patients enrolled
Trial Details
Trial ID
NCT06129968
Start Date
January 23 2024
End Date
July 31 2025
Last Update
May 16 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Sandwell and West Birmingham NHS TRUST
Birmingham, United Kingdom
2
Gateshead Health NHS Foundation Trust
Gateshead, United Kingdom
3
The Royal Wolverhampton NHS Trust
Wolverhampton, United Kingdom